Jefferies Financial Group Inc. Has $1.53 Million Stock Holdings in Axon Enterprise, Inc. (NASDAQ:AXON)

Jefferies Financial Group Inc. decreased its stake in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 99.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,580 shares of the biotechnology company's stock after selling 262,420 shares during the period. Jefferies Financial Group Inc.'s holdings in Axon Enterprise were worth $1,533,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of AXON. Capital World Investors boosted its stake in shares of Axon Enterprise by 86.4% in the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after purchasing an additional 841,772 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Axon Enterprise by 273.8% in the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock valued at $659,128,000 after purchasing an additional 812,337 shares in the last quarter. Norges Bank acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at $482,081,000. GQG Partners LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter valued at $478,349,000. Finally, Vanguard Group Inc. boosted its stake in shares of Axon Enterprise by 3.4% in the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock valued at $5,019,886,000 after purchasing an additional 275,959 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Trading Up 1.1%

NASDAQ:AXON traded up $8.21 on Monday, hitting $758.57. 520,984 shares of the stock were exchanged, compared to its average volume of 738,736. The stock has a market capitalization of $59.06 billion, a price-to-earnings ratio of 196.01, a P/E/G ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $765.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The company's 50-day moving average price is $624.56 and its 200 day moving average price is $611.72.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The company's quarterly revenue was up 31.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 EPS. On average, equities research analysts forecast that Axon Enterprise, Inc. will post 5.8 earnings per share for the current year.

Insider Activity

In related news, CRO Cameron Brooks sold 3,000 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $740.76, for a total value of $2,222,280.00. Following the completion of the transaction, the executive now directly owns 19,447 shares in the company, valued at approximately $14,405,559.72. The trade was a 13.36% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brittany Bagley sold 3,400 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $700.00, for a total value of $2,380,000.00. Following the completion of the transaction, the chief financial officer now owns 131,833 shares of the company's stock, valued at $92,283,100. This represents a 2.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 37,969 shares of company stock valued at $25,349,594 in the last ninety days. 4.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AXON. Barclays boosted their target price on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. JMP Securities restated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Craig Hallum downgraded shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research report on Monday, March 10th. Finally, Northcoast Research downgraded shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $652.73.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.